Targeted mass spectrometry analysis of the proteins IGF1, IGF2, IBP2, IBP3 and A2GL by blood protein precipitation

Journal of Proteomics

Volumn 113, Issue , 2015, Pages 29-37

  Such Sanmartín, Gerard ^a   Bache, Nicolai ^b   Callesen, Anne K ^a,c   Rogowska Wrzesinska, Adelina ^a   Jensen, Ole N ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Thermo Fisher Scientific   (United States)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anti doping; Blood samples; Insulin like growth factor; LC MS MS; SRM; Targeted analysis

Indexed keywords

ACETONITRILE; GLYCOPROTEIN; LEUCINE RICH ALPHA 2 GLYCOPROTEIN; PROTEOME; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG; IGF1 PROTEIN, HUMAN; IGF2 PROTEIN, HUMAN; IGFBP-2 PROTEIN, HUMAN; IGFBP3 PROTEIN, HUMAN; LRG1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACTION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA; PRECIPITATION; PROCESS DESIGN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN PURIFICATION; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; BLOOD; BREAST TUMOR; METABOLISM; PROCEDURES;

BREAST NEOPLASMS; FEMALE; FRACTIONAL PRECIPITATION; GLYCOPROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MASS SPECTROMETRY; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908006489     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.09.013     Document Type: Article

References (46)

1. Tambor V., Fucíková A., Lenco J., Kacerovský M., Rehácek V., Stulík J., et al. Application of proteomics in biomarker discovery: a primer for the clinician. Physiol Res 2010, 59:471-497.
2. Taguchi A., Hanash S.M. Unleashing the power of proteomics to develop blood-based cancer markers. Clin Chem 2013, 59:119-126.
3. Parker C.E., Pearson T.W., Anderson N.L., Borchers C.H. Mass-spectrometry-based clinical proteomics-a review and prospective. Analyst 2010, 135:1830-1838.
4. Granger J., Siddiqui J., Copeland S., Remick D. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics 2005, 5:4713-4718.
5. Anderson N.L., Anderson N.G., Pearson T.W., Borchers C.H., Paulovich A.G., Patterson S.D., et al. A human proteome detection and quantitation project. Mol Cell Proteomics 2009, 8:883-886.
6. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
7. Hortin G.L., Sviridov D., Anderson N.L. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem 2008, 54:1608-1616.
8. Anderson N.L. Counting the proteins in plasma. Clin Chem 2010, 56:1775-1776.
9. Millioni R., Tolin S., Puricelli L., Sbrignadello S., Fadini G.P., Tessari P., et al. High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS One 2011, 6:e19603.
10. Larsen M.R., Thingholm T.E., Jensen O.N., Roepstorff P., Jørgensen T.J.D. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol Cell Proteomics 2005, 4:873-886.
11. Tu C., Rudnick P.A., Martinez M.Y., Cheek K.L., Stein S.E., Slebos R.J.C., et al. Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 2010, 9:4982-4991.
12. Tamburro D., Fredolini C., Espina V., Douglas T.A., Ranganathan A., Ilag L., et al. Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc 2011, 133:19178-19188.
13. Greening D.W., Simpson R.J. Low-molecular weight plasma proteome analysis using centrifugal ultrafiltration. Methods Mol Biol 2011, 728:109-124.
14. Righetti P.G., Boschetti E., Candiano G. Mark Twain: How to fathom the depth of your pet proteome. J Proteomics 2012, 75:4783-4791.
15. Fonslow B.R., Stein B.D., Webb K.J., Xu T., Choi J., Park S.K., et al. Digestion and depletion of abundant proteins improves proteomic coverage. Nat Methods 2013, 10:54-56.
16. Such-Sanmartín G., Ventura-Espejo E., Jensen O.N. Depletion of abundant plasma proteins by poly(N-isopropylacrylamide-acrylic acid) hydrogel particles. Anal Chem 2014, 86:1543-1550.
17. Bosch J., Such-Sanmartín G., Segura J., Gutiérrez-Gallego R. Tracking growth hormone abuse in sport: performance of marker proteins in a controlled setting. Anal Chim Acta 2012, 745:118-123.
18. Pichini S., Ventura R., Palmi I., di Carlo S., Bacosi A., Langohr K., et al. Effect of physical fitness and endurance exercise on indirect biomarkers of growth hormone and insulin misuse: immunoassay-based measurement in urine samples. J Pharm Biomed Anal 2010, 53:1003-1010.
19. Kay R.G., Barton C., Velloso C.P., Brown P.R., Bartlett C., Blazevich A.J., et al. High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid Commun Mass Spectrom 2009, 23:3173-3182.
20. Chen T., Lukanova A., Grankvist K., Zeleniuch-Jacquotte A., Wulff M., Johansson R., et al. IGF-I during primiparous pregnancy and maternal risk of breast cancer. Breast Cancer Res Treat 2010, 121:169-175.
21. Probst-Hensch N.M., Steiner J.H.B., Schraml P., Varga Z., Zürrer-Härdi U., Storz M., et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin Cancer Res 2010, 16:1025-1032.
22. Milewicz T., Ryś J., Wójtowicz A., Stochmal E., Jach R., Krzysiek J., et al. Overexpression of P53 protein and local hGH, IGF-I, IGFBP-3, IGFBP-2 and PRL secretion by human breast cancer explants. Neuro Endocrinol Lett 2011, 32:328-333.
23. Qiu J., Yang R., Rao Y., Du Y., Kalembo F.W. Risk factors for breast cancer and expression of insulin-like growth factor-2 (IGF-2) in women with breast cancer in Wuhan City, China. PLoS One 2012, 7:e36497.
24. Foulstone E.J., Zeng L., Perks C.M., Holly J.M.P. Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. Endocrinology 2013, 154:1780-1793.
25. Cox H.D., Lopes F., Woldemariam G.A., Becker J.O., Parkin M.C., Thomas A., et al. Interlaboratory agreement of insulin-like growth factor 1 concentrations measured by mass spectrometry. Clin Chem 2014, 60:541-548.
26. Niederkofler E.E., Phillips D.A., Krastins B., Kulasingam V., Kiernan U.A., Tubbs K.A., et al. Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1. PLoS One 2013, 8:e81125.
27. Shi T., Su D., Liu T., Tang K., Camp D.G., Qian W.-J., et al. Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics 2012, 12:1074-1092.
28. Chertov O., Biragyn A., Kwak L.W., Simpson J.T., Boronina T., Hoang V.M., et al. Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry. Proteomics 2004, 4:1195-1203.
29. Merrell K., Southwick K., Graves S.W., Esplin M.S., Lewis N.E., Thulin C.D. Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. J Biomol Tech 2004, 15:238-248.
30. Kay R., Barton C., Ratcliffe L., Matharoo-Ball B., Brown P., Roberts J., et al. Enrichment of low molecular weight serum proteins using acetonitrile precipitation for mass spectrometry based proteomic analysis. Rapid Commun Mass Spectrom 2008, 22:3255-3260.
31. Barton C., Kay R.G., Gentzer W., Vitzthum F., Pleasance S. Development of high-throughput chemical extraction techniques and quantitative HPLC-MS/MS (SRM) assays for clinically relevant plasma proteins. J Proteome Res 2010, 9:333-340.
32. Kawashima Y., Fukutomi T., Tomonaga T., Takahashi H., Nomura F., Maeda T., et al. High-yield peptide-extraction method for the discovery of subnanomolar biomarkers from small serum samples. J Proteome Res 2010, 9:1694-1705.
33. De Bock M., de Seny D., Meuwis M.-A., Servais A.-C., Minh T.Q., Closset J., et al. Comparison of three methods for fractionation and enrichment of low molecular weight proteins for SELDI-TOF-MS differential analysis. Talanta 2010, 82:245-254.
34. Manza L.L., Stamer S.L., Ham A.-J.L., Codreanu S.G., Liebler D.C. Sample preparation and digestion for proteomic analyses using spin filters. Proteomics 2005, 5:1742-1745.
35. Löfgren L., Ståhlman M., Forsberg G.-B., Saarinen S., Nilsson R., Hansson G.I. The BUME method: a novel automated chloroform-free 96-well total lipid extraction method for blood plasma. J Lipid Res 2012, 53:1690-1700.
36. Neuhoff V., Arold N., Taube D., Ehrhardt W. Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie brilliant blue G-250 and R-250. Electrophoresis 1988, 9:255-262.
37. Callesen A.K., Vach W., Jørgensen P.E., Cold S., Tan Q., dePont Christensen R., et al. Combined experimental and statistical strategy for mass spectrometry based serum protein profiling for diagnosis of breast cancer: a case-control study. J Proteome Res 2008, 7:1419-1426.
38. Meiring H.D., van der Heeft E., ten Hove G.J., de Jong A.P.J.M. Nanoscale LC-MS(n): technical design and applications to peptide and protein analysis. J Sep Sci 2002, 25:557-568.
39. MacLean B., Tomazela D.M., Shulman N., Chambers M., Finney G.L., Frewen B., et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26:966-968.
40. Silva J.C., Gorenstein M.V., Li G.-Z., Vissers J.P.C., Geromanos S.J. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics 2006, 5:144-156.
41. Such-Sanmartín G., Sidoli S., Ventura-Espejo E., Jensen O.N. KYSS: Mass spectrometry data quality assessment for protein analysis and large-scale proteomics. Biochem Biophys Res Commun 2014, 445:702-707.
42. Aristoteli L.P., Molloy M.P., Baker M.S. Evaluation of endogenous plasma peptide extraction methods for mass spectrometric biomarker discovery. J Proteome Res 2007, 6:571-581.
43. Picotti P., Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 2012, 9:555-566.
44. Sanchis-Gomar F., Pareja-Galeano H., Brioche T., Martinez-Bello V., Lippi G. Altitude exposure in sports: the Athlete Biological Passport standpoint. Drug Test Anal 2013, 6:190-193.
45. Storch S., Kübler B., Höning S., Ackmann M., Zapf J., Blum W., et al. Transferrin binds insulin-like growth factors and affects binding properties of insulin-like growth factor binding protein-3. FEBS Lett 2001, 509:395-398.
46. Lee C.Y., Wu H.B., Suh D.S., Rechler M.M. Insulin-like growth factor-I (IGF-I) concentration in 150-kilodalton complexes containing human IGF-binding protein-3 (hIGFBP-3) after intravenous injection of adult rats with hIGFBP-3. Endocrinology 1997, 138:1649-1657.